Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results from the Pivotal Phase 3 PROTECT Trial – Encore presentation
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephopathy (PROTECT): 2-year Results From a Randomised Active-Controlled Phase 3 Trial
Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgA immune complexes in a mouse model of IgA nephropathy